Group items tagged

Endocrinology is the study of hormones and glands in the human body. The endocrine system produces and secretes hormones that regulate many bodily functions, including growth and development, metabolism, and reproductive health. Endocrinologists are physicians who specialize in diagnosing and treating hormonal imbalances and disorders. There are several reasons why you might consider seeing an endocrinologist. In this article, we'll explore some of the most common reasons people seek out the expertise of an endocrinologist. YOU HAVE DIABETES If you have diabetes, it is important to consider seeing an endocrinologist. Endocrinologists specialize in managing diabetes and can help you develop a personalized treatment plan to manage your blood sugar levels. They can also help you prevent or manage complications of diabetes, such as nerve damage, kidney disease, and eye problems. An endocrinologist can work with you to develop a healthy lifestyle plan that includes diet, exercise, and medication management. They can also help you adjust your treatment plan as needed to ensure that your diabetes is well-controlled. Seeing an endocrinologist can help you achieve better health outcomes and improve your overall quality of life.

In this post, we will share essential information about the most common Type 2 Diabetes symptoms and causes. What is Type 2 Diabetes? We all know blood glucose is our main source of energy and produced from the food that we eat. First of all, we try to understand what is type 2 diabetes!

In an announcement following Keir Starmer's and Wes Streeting's visit to a hospital in the East Midlands, Labour Party has unveiled a groundbreaking partnership with Virgin Media O2 aimed at ensuring every child with type 1 diabetes can access the latest medical technology to better manage diabetes. With the NHS providing patients with type 1 diabetes the option of an 'artificial pancreas' in the next five years to manage insulin levels and Continuous Glucose Monitors launched nearly 2 years ago to monitor children's glucose levels, the initiative aims to address the financial barrier hindering hundreds of families from benefiting from this breakthrough. Labour's plan to provide every child in need a smartphone, facilitating access to modern glucose monitors, aligns with the centre-leftist party's broader vision to harness technology for healthcare transformation. Announcing the partnership in an interview with ITV News, Keir Starmer, Labour Party Leader, highlighted the lack of equitable access to medical advancement amongst patients as "travesty" and "impact of fourteen years of Conservative chaos has had on the NHS", stating:

Managing diabetes revolves around making mindful food choices. Ms. Veena Kumari, a seasoned Consultant Dietitian at Kailash Deepak Hospital, underscores the pivotal role of diet in diabetes management.

Medical professionals often prescribe semaglutide to patients who have type 2 diabetes. Along with a balanced diet and regular exercise, it has also shown to be an incredibly efficient weight loss aid for patients. As the active ingredient in well-known brand-name drugs such as Wegovy, Ozempic, and Rybelsus, semaglutide is currently on everybody's lips. But what exactly is semaglutide? Does it really work for weight loss? We'll find an answer for you in this article, and explain the main benefits of using semaglutide for weight loss. What Is Semaglutide? A number of diabetic and weight loss medications, including Wegovy, Ozempic, and Rybelsus, have semaglutide as their active ingredient. This substance is a synthetic form of the hormone glucagon-like peptide-1 (GLP-1), that occurs naturally. Developed by the company Novo Nordisk, semaglutide was first approved by the FDA in 2017 as an injection for the treatment of adult type 2 diabetes (as part of the approval procedure for Ozempic). In 2019, the Food and Drug Administration approved a novel semaglutide form known as Rybelsus. Rybelsus was the first oral GLP-1 receptor agonist for the treatment of type 2 diabetes in the United States.

Diabetes is a life-altering ailment and there is no cure for it in the allopathic system of medicine. The only thing that allopathic medicines do is to relieve the symptoms and keep the blood sugar level low. On the other hand, Ayurveda classifies diabetes into three kinds - curable, pliable and incurable. In diabetes, the blood glucose level becomes high either due to lack of insulin produced by the pancreas or the body becoming resistant to insulin.

Nearly half of Type 1 diabetes patients in the NHS England are benefiting from the use of flash monitors that allow them to check their glucose levels more easily and regularly. The wearable gadget, linked with a phone app, has a sensor that attaches to the back of the arm, allowing patients to check their glucose with a simple one-second scan. Eligible patients can access the monitors on prescription from their local GP or diabetes team. The NHS is ahead of target to roll-out the monitors, as the independent health advisory NICE, confirmed it was beginning the consultation to expand the kit's access. As per recent data, around 125,000 patients now uses these monitors to help control their condition. The latest number shows that the NHS significantly exceeded its user target with more than 45 per cent of patients using the monitor.

Danish drug developer Novo Nordisk on Wednesday (February 1) warned of supply constraints on its best-selling drug. The company, which develops diabetes and obesity drugs, said it expected "periodic supply constraints" this year, partly driven by higher than expected demand for its blockbuster diabetes drug, Ozempic, and manufacturing constraints. "Supply of Ozempic cannot keep up with demand in some markets," Novo's Chief Financial Officer Karsten Munk Knudsen told journalists on Wednesday, but said Ozempic was available in the United States, the firm's biggest single market. Shortages of human growth hormone would also cause sales in its rare disease franchise to drop by a "mid-single digit" percentage in 2023, as its Norditropin drug would be out of stock in certain markets, Knudsen said.

National Institute of Health and Care Excellence (NICE) has not recommended 'Tirzepatide', also known as Mounjaro, developed by Eli Lilly, in its draft guidance issued on Tuesday (27 June) for treating type 2 diabetes in adults alongside diet and exercise. The independent NICE committee recognised the importance of new treatment options given that fewer than two-thirds of the adults with type 2 diabetes have adequate glucose control when using current treatment options. Evidence submitted to the committee from clinical trials showed the use of tirzepatide at any dose resulted in better glucose control and lower weight compared with semaglutide or insulin therapy. The weight reduction was more pronounced with higher doses of tirzepatide, while the effect on glucose levels seemed less dose-dependent. Similar effects were observed against all GLP-1 receptor agonists in company's network meta-analysis, but this was uncertain. The committee have asked the company to provide more data to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for GLP-1 receptor agonists used in the management of type 2 diabetes on Tuesday (27 June). "There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes Mellitus (T2DM)," said DHSC. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications and it is not expected to return to normal until at least mid-2024. Pharmacists are urged to refer to the SPS Tool for Medicines Shortages for an up-to-date supply stock situation and clinical guidance on alternative treatment options.

One of the long-standing medical mysteries is the diagnosis of diabetes in majority of patients suffering from high blood pressure. The reason for this had been unknown. But now, an international team of universities have made a breakthrough. The research, published online in 'Circulation Research', involved contributions from collaborating scientists in Brazil, Germany, Lithuania, and Serbia, as well as the UK and New Zealand. The important new discovery has shown that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body's control of blood sugar and blood pressure. Professor Julian Paton, a senior author, and director of Manaaki Manawa, The Centre for Heart Research at the University of Auckland, said: "We've known for a long time that hypertension and diabetes are inextricably linked and have finally discovered the reason, which will now inform new treatment strategies." GLP-1 is released from the wall of the gut after eating and acts to stimulate insulin from the pancreas to control blood sugar levels. This was known but what has now been unearthed is that GLP-1 also stimulates a small sensory organ called the carotid body located in the neck.

Eli Lilly's weight-loss medicine Mounjaro, also known as tirzepatide, will be available in the UK within weeks as a four-dose pre-filled injection pen. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the drug to treat adults with type 2 diabetes and for weight management in obese patients. Branded as Mounjaro KwikPen, the injection is to be used together with a reduced-calorie diet and increased physical activity, the regulator said. "The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people's health, is clear. "This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month's treatment, of one dose per week," said Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access.

The ayurvedic treatment for diabetes remains effective when compared to other treatment options. It helps to slash down the blood glucose levels and at the same time allows in strengthening the immune system. In this way, it prevents different organs to get damaged due to diabetes.

Diabetes drugs that also promote weight loss such as Novo Nordisk's Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer's disease. Diabetes regimens, from Ozempic to old mainstays like insulin and metformin, appear to address several different aspects of the metabolic system implicated in Alzheimer's disease, including a protein called amyloid and inflammation, researchers say. The hope is that improving glucose utilisation and tamping down inflammation in the entire body - including the brain - could slow progression of debilitating diseases like Alzheimer's and Parkinson's. Several scientists interviewed by Reuters news agency pointed to mounting research supporting testing diabetes drugs against neurodegenerative diseases. Results are years away and success uncertain. But interest has been buoyed by recent positive data on Alzheimer's drugs developed by Eisai with partner Biogen and by Eli Lilly demonstrating that removing sticky amyloid plaques accumulated in the brain can slow cognition decline caused by the fatal mind-wasting disease. Those successes followed decades of futility that had left many questioning the validity of the amyloid theory behind most experimental Alzheimer's drugs.

A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients. The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and weight-related health issues. The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings. The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity simultaneously. Although it is not authorised to use on the NHS as yet but future approvals can be predicted.

The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment. Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO). In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective. Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

Fellowship in Diabetes Mellitus is a programme of one year has been developed to address the gap in medical education & contact program and simulation training.

Non-insulin drug for diabetic patients

A pharmacy assistant has been jailed for three years and seven months for stealing £330,000 worth of diabetes-testing kits from his workplace. Abdul Nargoliya stole the products while working as a pharmacy assistant at a Lloydspharmacy counter inside a Sainsbury's supermarket in Fosse Park, Leicester where we was employed since 2012. The 30-year-old from Woodboy Street in Leicester was sentenced on Friday (May 26) after pleading guilty at Leicester Crown Court "to theft by an employee and concealing, transferring, converting criminal property". According to police an internal investigation launched at the pharmacy branch in July 2018 revealed that more than 22,000 test kits had been ordered since January 2017. Leicester Police said they identified Nargoliya as a suspect due to the time of the orders being placed matching up to his shift patterns. They arrested him in July 2018. Orders for the products were placed by telephone and CCTV footage showed Nargoliya handling them. It was noticed that during his shifts, the defendant would move the deliveries into a private consultation room and later leave with full carrier bags.